InvestorsHub Logo
Followers 49
Posts 3516
Boards Moderated 0
Alias Born 08/24/2005

Re: DewDiligence post# 1852

Tuesday, 03/17/2020 9:07:06 AM

Tuesday, March 17, 2020 9:07:06 AM

Post# of 3017
Baird upgrades 'defensive' Enanta, sees 'real COVID-19 potential'

Baird analyst Brian Skorney upgraded Enanta to Outperform from Neutral with a $60 price target. He sees the company having a defensive cash and royalty position and also views its core competencies in virology and respiratory disease as "among the best to tackle COVID-19," Skorney tells investors. Enanta's two-pronged development approach should give it the potential for a viable COVID-19 candidate to come from it pipeline in either the near or long term, Skorney added.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News